Cargando…
Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass
Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile and...
Autores principales: | Agarwal, Shvetank, Ullom, Beth, Al-Baghdadi, Yasser, Okumura, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275940/ https://www.ncbi.nlm.nih.gov/pubmed/22345956 http://dx.doi.org/10.4103/0970-9185.92458 |
Ejemplares similares
-
Argatroban for an alternative anticoagulant in HIT during ECMO
por: Rougé, Alain, et al.
Publicado: (2017) -
Successful Management of Hypothermic Cardiopulmonary Bypass in a Malignant Hyperthermia Susceptible Patient
por: Agarwal, Shvetank, et al.
Publicado: (2020) -
Argatroban for anticoagulation of a blood salvage system - an ex-vivo study
por: Beiderlinden, Martin, et al.
Publicado: (2016) -
Anticoagulation with Argatroban in a Patient with Heparin-Induced Thrombocytopenia and Renal Insufficiency Undergoing Orthotopic Heart Transplantation
por: Green, Michael Stuart, et al.
Publicado: (2021) -
Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
por: McGlynn, Fergal, et al.
Publicado: (2020)